Alivus Life Sciences Limited has submitted a regulatory disclosure to BSE Ltd. and the National Stock Exchange of India Ltd. regarding scheduled investor and analyst meetings. The disclosure is made pursuant to Regulation 30 and Para A of Part A of Schedule III of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.
The company has scheduled four one-on-one meetings with investors and analysts:
- August 28, 2026: Virtual meeting with Mirae Asset (US)
- September 1, 2026: In-person meeting with Emkay Global in Mumbai
- September 1, 2026: In-person meeting with SIMPL in Mumbai
- September 2, 2026: Virtual meeting with Lyptus Capital
The disclosure notes that the schedule and mode of meeting may undergo changes due to exigencies on the part of the Investor/Analyst/Company.